Recurrence of condylomata acuminata following cryotherapy is not prevented by systemically administered interferon
| Autor: | J DePamphilis, M B Alder, K Rittweger, J M O'Rourke, D J Pizzuti, L J Eron |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
Male Sexually transmitted disease medicine.medical_specialty Adolescent Injections Subcutaneous medicine.medical_treatment Population Alpha interferon Cryotherapy Dermatology Interferon alpha-2 Placebo Cryosurgery Genital warts Postoperative Complications Double-Blind Method Recurrence medicine Humans education Interferon alfa Chemotherapy education.field_of_study business.industry Interferon-alpha virus diseases medicine.disease Combined Modality Therapy Recombinant Proteins Surgery Infectious Diseases Condylomata Acuminata Female business Research Article medicine.drug |
| Zdroj: | Sexually Transmitted Infections. 69:91-93 |
| ISSN: | 1368-4973 |
| DOI: | 10.1136/sti.69.2.91 |
| Popis: | OBJECTIVE--To determine whether interferon alpha-2a, when utilised as adjuvant chemotherapy following ablation of condylomata acuminata (genital warts) by cryotherapy, is effective in the prevention of recurrences. DESIGN--Randomised, placebo-controlled, double-blind study. Statistical analysis was by 2-tailed Fisher's Exact Test. PATIENTS--97 patients with recurrent condylomata acuminata. INTERVENTION--49 patients were treated with cryotherapy plus subcutaneously administered interferon alpha-2a, and 48 received cryotherapy plus placebo. Of these, 36 and 37 patients, respectively, completed the study and were evaluable. MAIN OUTCOME MEASURE--Clinical eradication of condylomata for six months following adjuvant chemotherapy. RESULTS--By completion of the adjuvant chemotherapy, 10 (28%) interferon recipients and 16 (43%) placebo recipients experienced recurrences. At six months follow-up, 25 (69%) interferon and 27 (73%) placebo recipients experienced recurrences. In the six months following interferon therapy, only 31% of interferon and 27% of placebo recipients remained free of recurrences (p = 0.99). CONCLUSIONS--Interferon alpha-2a administered subcutaneously offers no benefit as a chemotherapeutic adjuvant to cryotherapy when used alone in the therapy of genital warts in this population of patients with recurrent condylomata. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|